NO328417B1 - Epotilonderivater samt deres syntese og anvendelse - Google Patents

Epotilonderivater samt deres syntese og anvendelse Download PDF

Info

Publication number
NO328417B1
NO328417B1 NO20006378A NO20006378A NO328417B1 NO 328417 B1 NO328417 B1 NO 328417B1 NO 20006378 A NO20006378 A NO 20006378A NO 20006378 A NO20006378 A NO 20006378A NO 328417 B1 NO328417 B1 NO 328417B1
Authority
NO
Norway
Prior art keywords
formula
compound
equiv
absent
mmol
Prior art date
Application number
NO20006378A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006378L (no
NO20006378D0 (no
Inventor
Kyriacos Costa Nicolaou
Nigel Paul King
Maurice Raymond Verschoyle Finlay
Yun He
Dionisios Vourloumis
Frank Roschangar
Antony Bigot
Hans Vallberg
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20006378D0 publication Critical patent/NO20006378D0/no
Publication of NO20006378L publication Critical patent/NO20006378L/no
Publication of NO328417B1 publication Critical patent/NO328417B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20006378A 1998-06-22 2000-12-14 Epotilonderivater samt deres syntese og anvendelse NO328417B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/102,602 US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs
PCT/EP1999/004287 WO1999067252A2 (fr) 1998-06-22 1999-06-21 Derives de l'epothilone, leur synthese et leur utilisation

Publications (3)

Publication Number Publication Date
NO20006378D0 NO20006378D0 (no) 2000-12-14
NO20006378L NO20006378L (no) 2001-02-21
NO328417B1 true NO328417B1 (no) 2010-02-15

Family

ID=22290705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006378A NO328417B1 (no) 1998-06-22 2000-12-14 Epotilonderivater samt deres syntese og anvendelse

Country Status (27)

Country Link
US (3) US6380394B1 (fr)
EP (2) EP1741715A1 (fr)
JP (1) JP4681732B2 (fr)
KR (3) KR20090066332A (fr)
CN (1) CN1192031C (fr)
AT (1) ATE343573T1 (fr)
AU (1) AU757854B2 (fr)
BR (1) BR9911420A (fr)
CA (1) CA2334342C (fr)
CY (1) CY1105863T1 (fr)
CZ (1) CZ301783B6 (fr)
DE (1) DE69933767T2 (fr)
DK (1) DK1089998T3 (fr)
ES (1) ES2273502T3 (fr)
HU (1) HUP0102711A3 (fr)
ID (1) ID28210A (fr)
IL (3) IL139784A0 (fr)
MX (1) MXPA00012443A (fr)
NO (1) NO328417B1 (fr)
NZ (1) NZ508622A (fr)
PL (1) PL197648B1 (fr)
PT (1) PT1089998E (fr)
RU (1) RU2227142C2 (fr)
SK (2) SK287864B6 (fr)
TR (1) TR200003844T2 (fr)
WO (1) WO1999067252A2 (fr)
ZA (1) ZA200007059B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
DE19820599A1 (de) * 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
WO2000050423A1 (fr) * 1999-02-22 2000-08-31 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Epothilones modifiees en c-21
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU2508201A (en) * 1999-11-24 2001-06-04 Basf Aktiengesellschaft Fungicidal melithiazole derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
WO2001092255A2 (fr) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Derives d'epothilone, procedes de production et methodes d'utilisation
AU2001291876C1 (en) * 2000-09-22 2006-11-23 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Triazolo-epothilones
AU2002213248A1 (en) * 2000-10-13 2002-04-22 The University Of Mississipi Synthesis of epothilones and relates analogs
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
EP1353667A1 (fr) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
CZ20032021A3 (cs) 2001-01-25 2004-05-12 Bristol@Myersásquibbácompany Způsoby podávání analogů epothilonu při léčbě rakoviny
WO2002066038A1 (fr) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Traitement de tumeurs refractaires a l'aide de derives d'epothilone
MXPA03007423A (es) 2001-02-20 2003-11-18 Bristol Myers Squibb Co Derivados de epotilona para tratamiento de tumores refractarios.
KR20030084952A (ko) * 2001-02-27 2003-11-01 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 에포틸론의 분해 및 에티닐 치환된 에포틸론
CA2440555A1 (fr) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combinaison d'analogues d'epothilones et d'agents chimiotherapeutiques servant au traitement de maladies proliferatives
WO2002098868A1 (fr) * 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Derives d'epothilone
CA2456280A1 (fr) * 2001-08-23 2003-03-06 Novartis Ag Analogues d'epothilone cyclopropyle et cyclobutyle
WO2003026744A1 (fr) * 2001-09-25 2003-04-03 Alcon, Inc. Utilisation d'epothilones et analogues en chirurgie ophtalmique
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
JP2005511062A (ja) * 2001-12-07 2005-04-28 ノバルティス アクチエンゲゼルシャフト タンパク質脱アセチル化酵素阻害剤についての生物マーカーとしてのアルファ−チューブリンアセチル化レベルの使用
RU2346686C2 (ru) 2002-01-14 2009-02-20 Новартис Аг Комбинации, включающие эпотилоны и антиметаболиты
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
EP1340498A1 (fr) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération
WO2003077903A1 (fr) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Derives c12-cyano epothilone
DK1483251T3 (da) * 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilon-derivater
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
BR0313198A (pt) * 2002-08-02 2005-07-12 Novartis Ag Derivados de epotilona
WO2004018478A2 (fr) * 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, leurs intermediaires, leurs analogues et leurs utilisations
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB0221312D0 (en) * 2002-09-13 2002-10-23 Novartis Ag Organic compounds
KR20050053681A (ko) 2002-09-23 2005-06-08 브리스톨-마이어스 스큅 컴퍼니 에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의ｘ-선 결정 구조
DK1553938T3 (da) * 2002-10-15 2007-03-26 Univ Louisiana State Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
EP1567487A4 (fr) 2002-11-15 2005-11-16 Bristol Myers Squibb Co Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (fr) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation d'epothilone pour le traitement de defauts de connectivité neuronale comme par exemple la schizophrenie et l'autisme
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1674098A1 (fr) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Formulations parenterales stables et tolérables des substances de haut réactivité ayant une solubilité basse ou inexistante dans l'eau
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007015929A2 (fr) * 2005-07-27 2007-02-08 University Of Toledo Analogues d'epothilone
US8003801B2 (en) * 2005-11-22 2011-08-23 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7653731B2 (en) * 2006-02-24 2010-01-26 Microsoft Corporation Management of connections to external data
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
KR20090095626A (ko) 2006-12-04 2009-09-09 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 ＣｐＧ 리치 ＤＮＡ를 이용한 조성물 및 암 치료 방법
AU2008212788A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
WO2008118327A1 (fr) * 2007-03-23 2008-10-02 University Of Toledo Analogues d'épothilone restreints en conformation en tant qu'agents anti-leucémiques
EP2065054A1 (fr) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinaisons comprenant une prostaglandine et leurs utilisations
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
US20110118343A1 (en) * 2008-07-03 2011-05-19 Pharma Mar, S. A. Antitumoral Macrolides
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (fr) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
CN103037903A (zh) 2010-05-18 2013-04-10 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
BR112013018534B1 (pt) 2011-01-20 2021-04-06 Board Of Regents, The University Of Texas System Agente de contraste, seus métodos de preparação, e produto de combinação
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
AU2012356894B2 (en) 2011-12-23 2018-01-18 Araris Biotech Ltd. Enzymatic conjugation of polypeptides
WO2014009426A2 (fr) 2012-07-13 2014-01-16 Innate Pharma Criblage d'anticorps conjugués
EP2916872B1 (fr) 2012-11-09 2019-02-27 Innate Pharma Etiquettes de reconnaissance pour la conjugaison à médiation par la tgase
WO2014075391A1 (fr) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 Composé du platine et de dérivé de l'acide malonique ayant un groupe partant contenant un groupe amino ou alkylamino
WO2014116594A1 (fr) * 2013-01-23 2014-07-31 The University Of Toledo Agents anticancéreux hautement sélectifs ciblant le cancer de poumon non à petites cellules et d'autres formes de cancer
WO2014140300A1 (fr) 2013-03-15 2014-09-18 Innate Pharma Conjugaison d'anticorps en phase solide médiée par la tgase
WO2014202773A1 (fr) 2013-06-20 2014-12-24 Innate Pharma Conjugaison enzymatique de polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2017066606A1 (fr) * 2015-10-16 2017-04-20 William Marsh Rice University Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci
WO2019092148A1 (fr) 2017-11-10 2019-05-16 Innate Pharma Anticorps avec des résidus de glutamine fonctionnalisés

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW221441B (fr) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ATE218556T1 (de) 1995-11-17 2002-06-15 Biotechnolog Forschung Gmbh Epothilon-derivate und deren herstellung
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
EP1201666A3 (fr) 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilones à chaine latérale modifiée
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
CA2299608A1 (fr) 1997-08-09 1999-02-18 Schering Aktiengesellschaft Nouveaux derives d'epothilone, leur procede de fabrication et leur utilisation pharmaceutique
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

Also Published As

Publication number Publication date
SK285647B6 (sk) 2007-05-03
SK19712000A3 (sk) 2001-09-11
RU2227142C2 (ru) 2004-04-20
ID28210A (id) 2001-05-10
TR200003844T2 (tr) 2001-04-20
IL139784A0 (en) 2002-02-10
HUP0102711A3 (en) 2002-09-30
AU4774899A (en) 2000-01-10
US7579366B2 (en) 2009-08-25
CN1306531A (zh) 2001-08-01
PL197648B1 (pl) 2008-04-30
DK1089998T3 (da) 2007-01-15
NO20006378L (no) 2001-02-21
JP4681732B2 (ja) 2011-05-11
ZA200007059B (en) 2002-01-30
CN1192031C (zh) 2005-03-09
CA2334342A1 (fr) 1999-12-29
PT1089998E (pt) 2007-01-31
WO1999067252A3 (fr) 2000-03-16
US6380394B1 (en) 2002-04-30
US6531497B1 (en) 2003-03-11
BR9911420A (pt) 2001-03-20
SK287864B6 (sk) 2012-02-03
PL345327A1 (en) 2001-12-17
IL139784A (en) 2010-05-17
EP1089998A2 (fr) 2001-04-11
DE69933767T2 (de) 2007-09-13
CA2334342C (fr) 2012-07-17
DE69933767D1 (de) 2006-12-07
JP2002518504A (ja) 2002-06-25
CZ20004769A3 (cs) 2001-07-11
IL182744A (en) 2010-05-17
WO1999067252A2 (fr) 1999-12-29
US20030203938A1 (en) 2003-10-30
ATE343573T1 (de) 2006-11-15
NZ508622A (en) 2003-07-25
ES2273502T3 (es) 2007-05-01
IL182744A0 (en) 2007-07-24
EP1089998B1 (fr) 2006-10-25
AU757854B2 (en) 2003-03-06
EP1741715A1 (fr) 2007-01-10
KR20010083060A (ko) 2001-08-31
HUP0102711A2 (hu) 2001-12-28
CZ301783B6 (cs) 2010-06-23
KR20080045298A (ko) 2008-05-22
HK1038358A1 (en) 2002-03-15
CY1105863T1 (el) 2011-02-02
MXPA00012443A (es) 2004-12-03
KR20090066332A (ko) 2009-06-23
KR100864742B1 (ko) 2008-10-22
NO20006378D0 (no) 2000-12-14

Similar Documents

Publication Publication Date Title
EP1089998B1 (fr) Derives de l'epothilone, leur synthese et leur utilisation
CA2505368C (fr) Trans-9,10-dehydroepothilones c et d, leurs analogues et leurs procedes de production
US6958401B2 (en) Method for synthesizing epothilones and epothilone analogs
WO1999067253A2 (fr) Desmethylepothilones
MXPA01008374A (es) Epotilonas c-21 modificadas.
DE60318224T2 (de) Epothilonderivate
JP2009007367A (ja) シクロプロピルおよびシクロブチルエポチロンアナログ
JP2002518504A5 (fr)
WO2018049127A1 (fr) Composés 1,2-dithiolane utiles dans la neuroprotection, les maladies et les états auto-immuns et cancéreux
US7317100B2 (en) Epothilone derivatives
US20050014767A1 (en) Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
JP2008504324A (ja) チアゾリノン非置換型キノリン
HK1102439A (en) Epothilone derivatives and their synthesis and use
AU2005223325B2 (en) Epothilone derivatives

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees